Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Ascendis Pharma (ASND) and Roche Holding AG (OtherRHHVF)

Tipranks - Tipranks - Tue Mar 3, 6:28AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on 10x Genomics (TXG – Research Report), Ascendis Pharma (ASND – Research Report) and Roche Holding AG (RHHVF – Research Report).

Claim 70% Off TipRanks Premium

10x Genomics (TXG)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on 10x Genomics today and set a price target of $25.00. The company’s shares closed last Friday at $23.05.

According to TipRanks.com, Arias is a 2-star analyst with an average return of 0.5% and a 44.6% success rate. Arias covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, BillionToOne, Inc. Class A, and Tempus AI, Inc. Class A. ;'>

10x Genomics has an analyst consensus of Moderate Buy, with a price target consensus of $20.08, which is a -7.0% downside from current levels. In a report issued on February 20, Barclays also maintained a Buy rating on the stock with a $22.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Ascendis Pharma (ASND)

In a report released today, Alex Thompson CFA from Stifel Nicolaus reiterated a Buy rating on Ascendis Pharma, with a price target of $325.00. The company’s shares closed last Friday at $233.50.

According to TipRanks.com, CFA is a 5-star analyst with an average return of 33.3% and a 67.9% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Dianthus Therapeutics. ;'>

Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $290.36, which is a 26.3% upside from current levels. In a report issued on February 17, Morgan Stanley also maintained a Buy rating on the stock with a $256.00 price target.

Roche Holding AG (RHHVF)

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Roche Holding AG today and set a price target of CHF350.00. The company’s shares closed last Friday at $480.00.

According to TipRanks.com, Vosser is a 3-star analyst with an average return of 1.6% and a 48.5% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Molecular Partners AG, Argenx Se, and Sanofi. ;'>

Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $447.85, a -6.7% downside from current levels. In a report issued on February 17, Deutsche Bank also maintained a Hold rating on the stock with a CHF340.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).